Onkologie. 2011:5(5):278-283

Chemotherapy and biological therapy of colorectal cancer with the aim to achieve

Jana Halámková1, Jiří Tomášek1, Šárka Bohatá2, Igor Kiss1
1 Klinika komplexní onkologické péče, Masarykův onkologický ústav a LF Masarykovy univerzity Brno
2 Radiodiagnostická klinika FN Brno a LF Masarykovy univerzity Brno

resectability of primarily unresectable disease

Colorectal cancer is one of the most common malignant tumors in the Czech Republic, and up to 40 % of patients are diagnosed at an

advanced stage. Surgical treatment is the primary modality of therapy leading to cure colorectal cancer even in advanced disease. The

introduction of new chemotherapeutic agents in practice greatly increased treatment options in patients who are not surgically curable.

In combination with biological therapy, it can be achieved operability even in recently unresectable stage and thereby significantly prolonged

life of patients with metastatic colorectal carcinoma. In patients with metastatic liver disease, both resectable or unresectable,

is usually used neoadjuvant chemotherapy/chemobiotherapy. Although there is not defined the best treatment regimen yet, a basic

requirement is low toxicity and high efficiency.

Keywords: colorectal cancer, liver metastases, neoadjuvant therapy

Published: November 1, 2011  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Halámková J, Tomášek J, Bohatá Š, Kiss I. Chemotherapy and biological therapy of colorectal cancer with the aim to achieve. Onkologie. 2011;5(5):278-283.
Download citation

References

  1. Ústav zdravotnických informací a statistiky ČR, Národní zdravotnický informační systém (NZIS), Národní onkologický registr (NOR), [citace 24.7.2011], dostupné z http://www.uzis.cz/publikace/novotvary-2008.
  2. Vyzula R, Žaloudík J. Rakovina tlustého střeva a konečníku, vybrané kapitoly. Maxdorf 2007: 287.
  3. Tomlinson JS, Jarnagin WR, DeMatteo RP, et al. Actual 10-year survival after resection of colorectal liver metastases defines cure. J Clin Oncol. 2007; 25(29): 4575-4580. Go to original source... Go to PubMed...
  4. Leonard GD, Brenner B, Kemeny NE. Neoadjuvant chemotherapy before liver resection for patients with unresectable liver metastases from colorectal carcinoma. J Clin Oncol 2005; 23(9): 2038-2048. Go to original source... Go to PubMed...
  5. Fong Y, Fortner J, Sun RL, Brennan MF, Blumgart LH. Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1 001 consecutive cases. Ann Surg 1999; 230(3): 309-321. Go to original source... Go to PubMed...
  6. Nordlinger B, Van Cutsem E, Gruenberger T, et al. Combination of surgery and chemotherapy and the role of targeted agents in the treatment of patients with colorectal liver metastases: recommendations from an expert panel. Ann Oncol 2009; 20(6): 985-992. Go to original source... Go to PubMed...
  7. Masi G, Cupini S, Marcucci L, et al. Treatment with 5-fluorouracil/folinic acid, oxaliplatin, and irinotecan enables surgical resection of metastases in patients with initially unresectable metastatic colorectal cancer. Ann Surg Oncol 2006; 13(1): 58-65. Go to original source... Go to PubMed...
  8. Nordlinger B, Sorbye H, Glimelius B, et al. Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial. Lancet 2008; 371: 1007-1016. Go to original source... Go to PubMed...
  9. Rothenberg M, Oza A, Bigelow R, et al: Superiority of oxaliplatin and fluorouracil-leucovorin compared with either therapy alone in patients with progressive colorectal cancer after irinotecan and fluorouracil-leucovorin: Interim results of a phase III trial. J Clin Oncol 2003; 21: 2059-2069. Go to original source... Go to PubMed...
  10. Saltz L, Cox JV, Blanke C, et al. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. N Engl J Med 2000; 343: 905-914. Go to original source... Go to PubMed...
  11. Van Cutsem E, Hoff PM, Harper P, et al. Oral capecitabine vs intravenous 5-flourouracil and leucovorin: Integrated efficacy data and novel analyses from two large, randomised phase III trials. Br J Cancer 2004; 90: 1190-1197. Go to original source... Go to PubMed...
  12. De Gramont A, Figer A, Seymour M, et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 2000; 18: 2938-2947. Go to original source... Go to PubMed...
  13. Tournigard C, Andre T, Achille E, el al. FOLFIRI followed by FOLFOX 6 or the reverse sequence in advanced colorectal cancer: A randomized GERCOR study. Journal of Clinical Oncology 22; 2004: 229-237. Go to original source... Go to PubMed...
  14. Douillard J, Cunningham D, Roth A, et al. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: A multicentre randomised trial. Lancet 2000; 355: 1041-1047. Go to original source... Go to PubMed...
  15. Twelwes C. The Xeloda Colorectal Cancer Group: capecitabine as first-line treatment in colorectal cancer. Pooled data from two large, phase III trials. European Journal of Cancer 2002; 38(Suppl 2): 15-20. Go to original source... Go to PubMed...
  16. Van Cutsem E, Rivera F, Berry S. Safety and Efficacy of Firstline Bevacizumab with FOLFOX, XELOX, FOLFIRI and Fluoropyrimidines in Metastatic Colorectal Cancer: The BEAT Study. Annals of Oncology 2009; 20(11): 1842-1847. Go to original source... Go to PubMed...
  17. Wong R, Cunningham D, Barbachano Y, et al. A multicentrestudy of capecitabine, oxaliplatin plus bevacizumab as perioperativetreatment of patients with poor-risk colorectal liver-only metastases not selected for upfront resection. AnnOncol. 2011 Feb 1 [Epub ahead of print]. Go to original source...
  18. Masi G, Loupakis F, Salvatore L, et al. Bevacizumab with FOLFOXIRI (irinotecan, oxaliplatin, fluorouracil, and folinate) as first-line treatment for metastatic colorectal cancer: a phase 2 trial. Lancet Oncol 2010; 11: 845-852. Go to original source... Go to PubMed...
  19. Van Cutsem E, Köhne CH, Hitre E, et al. Cetuximab andchemotherapy as initial treatment for metastatic colorectalcancer. N Engl J Med. 2009; 360(14): 1408-1417. Go to original source... Go to PubMed...
  20. Bokemeyer C, Bondarenko I, Makhson A, et al. Fluorouracil,leucovorin, and oxaliplatin with and without cetuximabin the first-line treatment of metastatic colorectal cancer. JClin Oncol 2009; 27(5): 663-671. Go to original source... Go to PubMed...
  21. Folprech G, Gruenberg T, Bechstein WO, et al. Tumor response and secondary resecability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab: the CELIM randomised phase 2 trial. The Lancet Oncology 2010; 11(1): 38-47. Go to original source... Go to PubMed...
  22. Garufi C, Torsello A, Tumolo S, et al. Cetuximab plus chronomodulated irinotecan, 5-fluorouracil, leucovorin and oxaliplatin as neoadjuvant chemotherapy in colorectal liver metastases: POCHER trial. Br J Cancer 2010; 103(10): 1542-1547. Go to original source... Go to PubMed...
  23. Chua TC, Saxena A, Liauw W, Kokandi A, Morris DL. Systematic review of randomized and nonrandomized trials of the clinical response and outcomes of neoadjuvant systemic chemotherapy for resectable colorectal liver metastases. Ann Surg Oncol 2010; 17(2): 492-501. Go to original source... Go to PubMed...
  24. Gruenberger B, Scheithauer W, Punzengruber R, Zielinski C, Tamandl D, Gruenberger T. Importance of response to neoadjuvant chemotherapy in potentially curable colorectal cancer liver metastases. BMC Cancer 2008; 8: 120. Go to original source... Go to PubMed...
  25. Gruenberger B, Tamandl D, Schueller J, et al. Bevacizumab, Capecitabine, and Oxaliplatin As Neoadjuvant Therapy for Patients With Potentially Curable Metastatic Colorectal Cancer. Journal of Clinical Oncology 2008; 26(11): 1830-1835. Go to original source... Go to PubMed...
  26. Adam R. Colorectal carcinoma with synchronous liver metastases. Br J Surg 2007; 94(2): 129-131. Go to original source... Go to PubMed...
  27. Alberts SR. Updated options for liver-limited metastatic colorectal cancer. Clin Colorectal Cancer 2008; 7(Suppl 2): 58-62. Go to original source... Go to PubMed...
  28. Nordlinger B, Benoist S. Benefits and risks of neoadjuvant therapy for liver metastases. J Clin Oncol 2006; 4(31): 954-4955. Go to original source... Go to PubMed...
  29. Benoist S, Bouquet A, Penna C, et al. Complete response of colorectal cancor metastase after chemotherapy: Does it mean cure? J Clin Oncol 2006; 24: 3939-3945. Go to original source... Go to PubMed...
  30. Fernandez FG, Ritter J, Goodwin JW, Linehan DC, Hawkins WG, Strasberg SM. Effect of steatohepatitis associated with irinotecan or oxaliplatin pretreatment on resectability of hepatic colorectal metastases. J Am Coll Surg 2005; 200: 845. Go to original source... Go to PubMed...
  31. Ribero D, Wang H, Donadon M, et al. Bevacizumab improves pathologic response and protects against hepatic injury in patients treated with oxaliplatin-based chemotherapy for colorectal liver metastases. Cancer 2007; 110(12): 2761-2767. Go to original source... Go to PubMed...
  32. Portier G, Elias D, Bouche O, et al. Multicenter randomized trial of adjuvant fluorouracil and folinic acid compared with surgery alone after resection of colorectal liver metastases: FFCD ACHBTH AURC 9002 trial. J Clin Oncol 2006; 24: 4976-4982. Go to original source... Go to PubMed...
  33. Mitry E, Fields A, Bleiberg H, et al. Adjuvant chemotherapy after potentially curative resection of metastases from colorectal cancer: A meta-analysis of two randomized trials. J Clin Oncol 2008; 26(30): 4906-4911. Go to original source... Go to PubMed...
  34. Ychou M, Hohenberger W, Thezenas S, et al. A randomized phase III study comparing adjuvant 5-fluorouracil/folinic acid with FOLFIRI in patiens following complete resection of liver metastases from colorectal cancer. Ann Oncol 2009; 20(12): 1964-1970. Go to original source... Go to PubMed...




Oncology

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.